Payment overview · 2025
General Payments
$1,668.30
67 reported records · 20 companies
Healthcare provider profile · identity verified
Waleed S Lashin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLIFTON, NJ · NPI 1477590644
Verified facts
What the public records show
CMS Open Payments records show Waleed S Lashin, MD received $1,668.30 in general payments during 2025 across 67 reported records.
ABBVIE INC. accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Otezla, Ozempic, Prolia, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 369 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 420 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $339.19 | 20.3% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $172.82 | 10.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $154.80 | 9.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $137.31 | 8.2% | 9 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $126.37 | 7.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $122.88 | 7.4% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.25 | 5.1% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $74.73 | 4.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $56.48 | 3.4% | 3 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $55.24 | 3.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.22 | 3.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.71 | 3.1% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $50.67 | 3.0% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $46.88 | 2.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.80 | 2.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $34.87 | 2.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.56 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.19 | 1.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.71 | 0.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.62 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,668.30 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $179.40 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $172.82 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $139.65 | 2 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $126.37 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $122.88 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $103.27 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $87.59 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $75.04 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $70.22 | 4 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $55.24 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.06 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $52.67 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.71 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $50.67 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $46.88 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $44.48 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $34.79 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $34.79 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.60 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.25 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.15 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 369 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 251 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 179 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 420 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 28 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 99 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
179 | 39 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
369 | 75 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
251 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
251 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
420 | 64 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
99 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1116 | 299 |
| Amlodipine Besylate | Amlodipine Besylate | 720 | 192 |
| Metformin Hcl | Metformin Hcl | 707 | 182 |
| Gabapentin | Gabapentin | 576 | 128 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 482 | 128 |
| Metoprolol Succinate | Metoprolol Succinate | 454 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 431 | 110 |
| Omeprazole | Omeprazole | 424 | 94 |
| Ozempic | Semaglutide | 420 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 406 | 105 |
| Lisinopril | Lisinopril | 404 | 95 |
| Farxiga | Dapagliflozin Propanediol | 369 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 339 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 323 | 85 |
| Famotidine | Famotidine | 287 | 80 |
| Jardiance | Empagliflozin | 251 | 51 |
| Losartan Potassium | Losartan Potassium | 250 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 236 | 62 |
| Furosemide | Furosemide | 235 | 61 |
| Montelukast Sodium | Montelukast Sodium | 231 | 57 |
| Ezetimibe | Ezetimibe | 228 | 55 |
| Diclofenac Sodium | Diclofenac Sodium | 227 | 74 |
| Alendronate Sodium | Alendronate Sodium | 217 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 208 | 53 |
| Glimepiride | Glimepiride | 200 | 51 |
| Meloxicam | Meloxicam | 194 | 59 |
| Vascepa | Icosapent Ethyl | 183 | 39 |
| Finasteride | Finasteride | 182 | 41 |
| Donepezil Hcl | Donepezil Hcl | 180 | 45 |
| Linzess | Linaclotide | 179 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 48 |
| Mirtazapine | Mirtazapine | 165 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 42 |
| Carvedilol | Carvedilol | 159 | 44 |
| Metformin Hcl Er | Metformin Hcl | 158 | 38 |
| Eliquis | Apixaban | 145 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 141 | 57 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 135 | 46 |
| Memantine Hcl Er | Memantine Hcl | 123 | 29 |
| Januvia | Sitagliptin Phosphate | 108 | 25 |
| Azithromycin | Azithromycin | 105 | 81 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 100 | 35 |
| Rybelsus | Semaglutide | 99 | 19 |
| Sucralfate | Sucralfate | 91 | 16 |
| Prednisone | Prednisone | 90 | 61 |
| Valsartan | Valsartan | 90 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 27 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 89 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 27 |
| Memantine Hcl | Memantine Hcl | 86 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 84 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 81 | 28 |
| Calcitriol | Calcitriol | 80 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 79 | 70 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 78 | 18 |
| Simvastatin | Simvastatin | 78 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 77 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 77 | 29 |
| Azelastine Hcl | Azelastine Hcl | 76 | 25 |
| Humalog Kwikpen U-100 | Insulin Lispro | 75 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 75 | 14 |
| Methylprednisolone | Methylprednisolone | 75 | 65 |
| Xarelto | Rivaroxaban | 75 | 16 |
| Enalapril Maleate | Enalapril Maleate | 73 | 17 |
| Lidocaine | Lidocaine | 72 | 28 |
| Nitroglycerin | Nitroglycerin | 70 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 17 |
| Mounjaro | Tirzepatide | 67 | 11 |
| Pregabalin | Pregabalin | 67 | 17 |
| Allopurinol | Allopurinol | 66 | 13 |
| Fenofibrate | Fenofibrate,micronized | 65 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 17 |
| Fenofibrate | Fenofibrate | 64 | 13 |
| Novolog Flexpen | Insulin Aspart | 64 | 19 |
| Myrbetriq | Mirabegron | 63 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 16 |
| Alprazolam | Alprazolam | 61 | 22 |
| Propranolol Hcl | Propranolol Hcl | 61 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 60 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 13 |
| Ammonium Lactate | Ammonium Lactate | 52 | 14 |
| Glipizide | Glipizide | 52 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | suppressed |
| Tradjenta | Linagliptin | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 48 | 15 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Lactulose | Lactulose | 47 | 11 |
| Nifedipine Er | Nifedipine | 47 | 16 |
| Sertraline Hcl | Sertraline Hcl | 46 | 13 |
| Atenolol | Atenolol | 45 | 13 |
| Bydureon Bcise | Exenatide Microspheres | 45 | suppressed |
| Hydrocortisone | Hydrocortisone | 45 | 21 |
| Ibuprofen | Ibuprofen | 44 | 22 |
| Spironolactone | Spironolactone | 44 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 40 |
| Ketoconazole | Ketoconazole | 42 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 41 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Repatha Sureclick | Evolocumab | 39 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 38 | 12 |
| Meclizine Hcl | Meclizine Hcl | 38 | 18 |
| Procto-Med Hc | Hydrocortisone | 38 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | 12 |
| Fluconazole | Fluconazole | 37 | 23 |
| Trazodone Hcl | Trazodone Hcl | 37 | suppressed |
| Naproxen | Naproxen | 36 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Cephalexin | Cephalexin | 35 | 30 |
| Metformin Er Gastric | Metformin Hcl | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 20 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 30 | suppressed |
| Clonazepam | Clonazepam | 30 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 30 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | 16 |
| Prolia | Denosumab | 28 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | 20 |
| Constulose | Lactulose | 24 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | 13 |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 15 |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Ciclopirox | Ciclopirox | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 21 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 20 | 20 |
| Repatha Pushtronex | Evolocumab | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Alogliptin | Alogliptin Benzoate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Admelog Solostar | Insulin Lispro | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 15 | 14 |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 12 |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| V-Go 30 | Sub-Q Insulin Device, 30 Unit | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Mupirocin | Mupirocin Calcium | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,668.30 · 67 records | ABBVIE INC. | AFREZZA, AIRSUPRA, Auvelity, CREON, CRYSVITA, Cologuard Collection Kit, Da Vinci Surgical System, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, LEQVIO, LINZESS, Leqembi, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error